LEO Pharma announces key results of Phase 2 TRAPEDS-1 trial evaluating pharmacokinetics and safety of tralokinumab ...

BALLERUP, Denmark--(BUSINESS WIRE)--LEO Pharma, a global leader in medical dermatology, today announced that Dr. Monica Shaw, M.D., and Nathalie Joannes will join the executive leadership team adding ...

The COBRA study is the first to compare an IL-17 receptor blocker with an IL-23 inhibitor in patients who do not respond adequately to an older biologic BALLERUP, Denmark--(BUSINESS WIRE)--LEO Pharma ...

Leo Pharma is launching a new U.S. healthcare awareness campaign aimed at doctors to boost their understanding of a specific type of eczema. Called “Talk to the Hand,” this campaign aims to spread ...

LEO Pharma A/S, a global leader in medical dermatology, today announces its scientific program for the European Society of Contact Dermatitis (ESCD) Congress 2026, taking place in Copenhagen, Denmark.

Nordic Capital has made an investment in LEO Pharma, a Danish medical dermatology company. No financial terms were disclosed. Moelis & Company served as financial advisor and Plesner acted as legal ...

Transaction Provides Timber Stockholders with Upfront Cash Consideration and Downstream Value through Contingent Value Rights Total Transaction Value of up to $36 million Transaction Expected to Close ...

Leo Pharma's latest "hackathon" brought together scientists and entrepreneurs to find dermatology solutions for people of color. The third "Hacking Dermatology Innovation Challenge" tasked ...

The campaign focuses on educating the one in 10 U.S. adults living with chronic hand eczema (CHE), particularly the one in three patients who have never heard the specific name of their condition.

Leo Pharma has shared phase 2b data on its eczema prospect temtokibart, reporting that the top three doses of the IL-22RA1 blocker beat placebo on the primary endpoint. Temtokibart is designed to ...

(RTTNews) - Gilead Sciences, Inc. (GILD) and LEO Pharma entered strategic partnership to develop and commercialize LEO Pharma's small molecule oral STAT6 (signal transducer and activator of ...

The Danish pharmaceutical company Leo Pharma A/S plans to acquire assets worth up to 5 billion kronor ($800 million) before the IPO. This is reported in a press release from Leo Pharma. From the point ...